ทวีตที่ปักหมุด
Melissa Hardy
36 posts

Melissa Hardy
@Merlo1969
PhD Candidate, University of Queensland.
Brisbane, Queensland เข้าร่วม Nisan 2014
197 กำลังติดตาม56 ผู้ติดตาม
Melissa Hardy รีทวีตแล้ว

👨🔬 👩🔬 Are you working in epidemiology, clinical trials or research using target trial emulation (TTE)?
Why don’t you join us for our symposium exploring the latest methodological developments and applications of TTE and other frameworks?
Sign up 🔽
bit.ly/TTE_25

English

@drpeterlange Right. Does all ITP qualify? Do you have to fail steroids first? Are there selection criteria?
English
Melissa Hardy รีทวีตแล้ว

🦠 Our new paper highlights cost and access barriers to antifungals in Vietnam.
Annual drug costs for major IFIs are $209.1M, so it’s vital to get these right.
👇🏻
✅ Cost-effective procurement 💵
✅ antifungal stewardship 💊
academic.oup.com/mmy/article/63…
#AMS #mycology @Sydney_ID

English
Melissa Hardy รีทวีตแล้ว

Read the latest article from Professor Dame Sally Davies (UK Special Envoy on AMR) and Nikolaj Gilbert (President & CEO of PATH).
There is a looming antibiotic emergency, and the time for global action is now:
telegraph.co.uk/global-health/…
English
Melissa Hardy รีทวีตแล้ว

Exciting news! 🎉 NUS launches its Master's in Infectious Disease Emergencies in July/Aug 2025. Tailored coursework, hybrid learning, and networking opportunities await! Make an impact! 🌍💼 Register here👉forms.office.com/pages/response…
#InfectiousDiseases #NUS
English

Whilst functionality and interpretation of both approaches differ, the use of a rank-based composite endpoint can provide more insights into treatment effect than a single binary endpoint i.e. mortality
cmi-comms.com/article/S2950-…
@davidantibiotic @padstamundo #UQCCR @MerinoTrial
English
Melissa Hardy รีทวีตแล้ว

🌍💡 Join us to design the next version of ACORN2 and ACORN-HAI by taking a 3-minute survey!! Have your say by end of October. Your input is invaluable! 🛑🦠💊 #AMR #AntimicrobialResistance #HealthcareInnovation 💻📊
👉 nus.syd1.qualtrics.com/jfe/form/SV_8b…
English
Melissa Hardy รีทวีตแล้ว

🆕️⚡️⚡️Exploring desirability of outcome ranking & generalised pairwise comparisons as endpoints in serious infections: Post hoc application/MERINO
The application of DOOR & GPC approaches in this post hoc demonstrated superiority of mero over pip tazo
sciencedirect.com/science/articl…



English
Melissa Hardy รีทวีตแล้ว

Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial
bit.ly/3RKNEwq
English

Lovely to meet my collaborator and long distance colleague again @b_fekade working to raise the bar re: opat stability of antimicrobials. Such a great partnership between 🇬🇧 and 🇦🇺 @BSACandJAC @jasonroberts_pk @CRE_RESPOND @raseaton66

English

@MGilchrist123 @b_fekade @jasonroberts_pk @raseaton66 @jamiesonce Congrats @b_fekade, @jasonroberts_pk and team. So amazing to see this finally published.
English
Melissa Hardy รีทวีตแล้ว

Great to see this - Evaluation of stability of ceftazidime/avibactam in elastomeric infusion devices used for OPAT. 🇬🇧 & 🇦🇺 partnership in this space continues @b_fekade @jasonroberts_pk @raseaton66 @jamiesonce & more academic.oup.com/jacamr/article…
English

AMR challenges RCT's which are critical to provide evidence in clinical decision making. We applied the win ratio method post hoc to the MERINO trial to provide more evidence and insights in ID trials. youtu.be/4UnG48cKVkY @davidantibiotic @padstamundo @InfectiousMoYin

YouTube
English

Very privileged to be a part of “Making Waves” which will air on @SBSVICELAND in celebration of International Women’s Day, friday 8th March, 9.25pm sbs.com.au/whats-on/artic…
English
Melissa Hardy รีทวีตแล้ว

Win ratio analyses of piperacillin-tazobactam versus meropenem for ceftriaxone non-susceptible Escherichia coli or Klebsiella pneumoniae bloodstream infections: Post-hoc insights from the MERINO trial
✅ Just Accepted
🔗 bit.ly/3uloUm4

English